Blu buy bolsters Puracap in US softgel market

Image: iStock

Puracap has bought Blu Pharmaceuticals and its Puerto Rican manufacturing site and plans to double oral dose production capacity.

The acquisition of Blu Pharmaceutical and its subsidiary Blu Caribe last week adds oral tablet and capsule dosage forms to Puracap’s softgel manufacturing capabilities. It also provides the firm with greater access to the US market, president Sean Weeks told

“We already have a US FDA compliant soft gel manufacturing site in Wuhan, China and currently market over 25 different OTC pharmaceutical products into the US market from that location,” he said, but the deal includes the addition of Blu’s 145,000 sq ft cGMP compliant manufacturing facility in Dorado, Puerto Rico, and 185,000 sq ft of warehouse and distribution space in Franklin, Kentucky.

The merged company – to be known as Puracap International – will initially have an annual capacity in excess of three billion doses, but Weeks said there are “plans to double that capacity through infrastructure investments and market expansion of owned and acquired ANDA’s as well as contract manufacturing.”

Softgel market

The merger is the latest movement in the capsule space over the past few years. In 2012, Qualicaps was acquired by Mitsubishi Chemical Holdings, while months later Capsugel upped its dosage forms business by buying Scottish contract development and manufacturing organisation (CDMO) Encap.

Concurrently, CDMO Catalent has been bolstering its softgel capacity through acquisitions in China and Brazil, while rival contractor Patheon paid $255m for Banner Pharmacaps in 2012 and subsequently subsequently sold its Mexican operations to OTC specialist Perrigo.

Weeks told us his company’s acquisition places Puracap International among the major players in this space, with the opportunity to provide unique and broad portfolio options in segments we are strategically aligned with currently with the Blu Pharmaceuticals client base. 

US government supply, tech transfers and new product development will provide us with flexible and collaborative project needs,” he continued, adding: “We can offer contract manufacturing for clients lacking in capacity.”

Related News

Image: iStock/Viperfzk

Catalent's oral biz hit by Beinheim suspension and low modified release demand

Rayaldee is made at Catalent's St. Petersburg, Florida softgel plant

Opko extended-release kidney disease drug approved after Catalent 483 delay

Puracap's Wuhan site passes US FDA inspection prompted by ANDA

Puracap's Wuhan site passes US FDA inspection prompted by ANDA


Qualicaps spent $43m to gain control of Brazilian capsule market, reports

Patheon to buy Banner for softgel caps

Patheon to buy Banner Pharmacaps for $255m

Growing demand for vegetarian capsules despite their cost, Capsugel

Growing demand for vegetarian capsules despite their cost, says Capsugel

Catalent Completes Chinese Softgel Acquisition

Catalent Completes Chinese Softgel Acquisition

Capsule talks softegl tech at CPhI Frankfurt

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Patheon has sold its ex-Banner operations in Mexico to Perrigo

Perrigo enters softgel space buying ex-Banner operations for $34m from Patheon

Molecular Profiles buys tech for liquid capsule manufacture

Molecular Profiles buys tech for liquid capsule manufacture

Catalent boosts services at Eberbach, Germany site

Catalent to offer integrated services in Germany through softgel expansion

Related Products

See more related products